PMC8370582_01
IBS-SSS (Irritable Bowel Syndrome Severity Scoring System) single items (A) and global score (B) at T0 (first check-up), at T1 (after six weeks from T0), at T2 (after 12 weeks from T0) and at T3 (after 24 weeks from T0).
PPA-15-1763-g0001.jpg
PMC8370582_01_PPA-15-1763-g0001.jpg
f0001
Severity Scoring System (IBS-SSS) (Figure 1A and B: T0) and a homemade questionnaire in which the symptoms were assessed by a visual analogue scale (VAS), where 0 means lack of the symptom and 10 means the greatest possible symptom severity (Figure 2: T0). She also reported weight loss (3 kg in the previous 2 months) and an impaired quality of life, evaluated by using 36-item Short Form Health Survey (SF-36) questionnaire, mainly linked to the domains: role limitations (emotional problems), vitality, emotional well-being, social functioning, general health and health change (Figure 3: T0). At a check control 6 weeks after the first clinical assessment (T1), symptoms were practically unchanged (Figures 1-3). In comparison with T2, no relevant changes of BSC, daily bowel movements, abdominal pain, fecal urgency, IBS-SSS, and SF 36 scores, were observed, but moderate abdominal bloating and flatulence with an occasional mild abdominal pain (Figures 1-3).
Daily bowel movements, Bristol Stool Form Scale (BSFS), and a homemade bowel habits questionnaire at T0 (first check-up), at T1 (after six weeks from T0), at T2 (after 12 weeks from T0) and at T3 (after 24 weeks from T0). Apart from daily bowel movements and BSFS the other parameters were evaluated using a visual analogue scale where 0 was the absence of symptom and 10 was the greatest possible symptom severity.
PPA-15-1763-g0002.jpg
PMC8370582_01_PPA-15-1763-g0002.jpg
f0002
Severity Scoring System (IBS-SSS) (Figure 1A and B: T0) and a homemade questionnaire in which the symptoms were assessed by a visual analogue scale (VAS), where 0 means lack of the symptom and 10 means the greatest possible symptom severity (Figure 2: T0). She also reported weight loss (3 kg in the previous 2 months) and an impaired quality of life, evaluated by using 36-item Short Form Health Survey (SF-36) questionnaire, mainly linked to the domains: role limitations (emotional problems), vitality, emotional well-being, social functioning, general health and health change (Figure 3: T0). At a check control 6 weeks after the first clinical assessment (T1), symptoms were practically unchanged (Figures 1-3). In comparison with T2, no relevant changes of BSC, daily bowel movements, abdominal pain, fecal urgency, IBS-SSS, and SF 36 scores, were observed, but moderate abdominal bloating and flatulence with an occasional mild abdominal pain (Figures 1-3).
SF 36 (IQOLA SF 36 Italian version 1.6) for assessing the health-related quality of life at T0 (first check-up), at T1 (after six weeks from T0), at T2 (after 12 weeks from T0) and at T3 (after 24 weeks from T0).
PPA-15-1763-g0003.jpg
PMC8370582_01_PPA-15-1763-g0003.jpg
f0003
Severity Scoring System (IBS-SSS) (Figure 1A and B: T0) and a homemade questionnaire in which the symptoms were assessed by a visual analogue scale (VAS), where 0 means lack of the symptom and 10 means the greatest possible symptom severity (Figure 2: T0). She also reported weight loss (3 kg in the previous 2 months) and an impaired quality of life, evaluated by using 36-item Short Form Health Survey (SF-36) questionnaire, mainly linked to the domains: role limitations (emotional problems), vitality, emotional well-being, social functioning, general health and health change (Figure 3: T0). At a check control 6 weeks after the first clinical assessment (T1), symptoms were practically unchanged (Figures 1-3). In comparison with T2, no relevant changes of BSC, daily bowel movements, abdominal pain, fecal urgency, IBS-SSS, and SF 36 scores, were observed, but moderate abdominal bloating and flatulence with an occasional mild abdominal pain (Figures 1-3).
PMC8370582_02
PMC8370582_03
PMC8370582_04
Diarrhoea following treatment with GELSECTAN .
PPA-15-1763-g0004.jpg
PMC8370582_04_PPA-15-1763-g0004.jpg
f0004
The patient reported a complete resolution of the diarrhoea just after 3 weeks (Figure 4), while abdominal pain disappeared after 6 weeks (Figure 5); a mild bloating persisted after the end of the treatment.
Abdominal pain following treatment with GELSECTAN . VAS scale from 0 to 10 (0 = No pain and 10 = Worst pain).
PPA-15-1763-g0005.jpg
PMC8370582_04_PPA-15-1763-g0005.jpg
f0005
The patient reported a complete resolution of the diarrhoea just after 3 weeks (Figure 4), while abdominal pain disappeared after 6 weeks (Figure 5); a mild bloating persisted after the end of the treatment.